The most successful treatment options against non-resettable metastatic melanoma are immunotherapies with antibodies directed against CTLA-4 and PD-1 [6,7] or their combination (small kinase and checkpoint inhibitors) [8,9,10]. This evidence concerns the gene CTLA4 and metastatic melanoma.